# Efficacy and Safety From a Recombinant Folding Variant of Bet v 1

> **NCT00554983** · PHASE3 · COMPLETED · sponsor: **Allergopharma GmbH & Co. KG** · enrollment: 255 (actual)

## Conditions studied

- Allergy

## Interventions

- **BIOLOGICAL:** recombinant birch pollen allergen
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT00554983
- **Lead sponsor:** Allergopharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2010-06
- **Final completion:** 2012-05
- **Target enrollment:** 255 (ACTUAL)
- **Last updated:** 2013-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00554983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00554983, "Efficacy and Safety From a Recombinant Folding Variant of Bet v 1". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00554983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*